

Summary paragraph

Can CAR-T cells replace allo SCT in RR DLBCL? Yes

The mainstay of DLBCL treatment is chemotherapy. Relapsed or refractory disease may benefit from immunologic approaches. Allo SCT is of moderate activity, and the existence of a graft-versus-lymphoma effect is questionable. Early and late side effects limit its application to patients in good health, conditions mainly met by the young age group. CAR-T cells have a well-defined immunologic target. Side effects are limited to the first few weeks after treatment, and there is no age limit to the procedure. Therefore, in RR DLBCL, CAR-T cells have wider applicability and may be more efficient than allo SCT.